Evidence map›Paper›PMID 37673901›Full record

ArticleNature communications2023

Xanomeline displays concomitant orthosteric and allosteric binding modes at the M

Wessel A C Burger, Vi Pham, Ziva Vuckovic, Alexander S Powers, Jesse I Mobbs, Yianni Laloudakis, Alisa Glukhova, Denise Wootten, Andrew B Tobin, Patrick M Sexton and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Novel drug treatments for schizophrenia.Nature reviews. Drug discovery · 2026
    Review
  5. Targeting muscarinic receptors for treating schizophrenia.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Review
  6. Xanomeline-Trospium for the Treatment of Schizophrenia.Focus (American Psychiatric Publishing) · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Lipid Trolling to Optimize AJournal of medicinal chemistry · 2024
    Article
  12. Review
  13. Antipsychotic displays dual GPCR binding mode.Nature reviews. Drug discovery · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 4 countries.

Wessel A C Burger *Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.ORCID http://orcid.org/0000-0003-2047-2593
Vi Pham *Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.
Ziva Vuckovic *Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.
Alexander S Powers *Department of Chemistry, Stanford University, Stanford, CA, 94305, USA.
Jesse I MobbsDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.ORCID http://orcid.org/0000-0001-6979-1427
Yianni LaloudakisDepartment of Chemistry, Stanford University, Stanford, CA, 94305, USA.
Alisa GlukhovaDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.ORCID http://orcid.org/0000-0003-4146-965X
Denise WoottenDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.ORCID http://orcid.org/0000-0003-4563-1642
Andrew B TobinThe Advanced Research Centre (ARC), Centre for Translational Science, School of Biomolecular Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, G12 8QQ, UK.ORCID http://orcid.org/0000-0002-1807-3123
Patrick M SextonDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.ORCID http://orcid.org/0000-0001-8902-2473
Steven M PaulKaruna Therapeutics, Boston, MA, 02110, USA.
Christian C FelderKaruna Therapeutics, Boston, MA, 02110, USA.
Radostin DanevGraduate School of Medicine, University of Tokyo, N415, 7-3-1 Hongo, Bunkyo-ku, 113-0033, Tokyo, Japan.ORCID http://orcid.org/0000-0001-6406-8993
Ron O DrorDepartments of Computer Science, Structural Biology, and Molecular and Cellular Physiology, Stanford University, Stanford, CA, 94305, USA. ron.dror@stanford.edu.ORCID http://orcid.org/0000-0002-6418-2793
Arthur ChristopoulosDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia. arthur.christopoulos@monash.edu.ORCID http://orcid.org/0000-0003-4442-3294
Celine ValantDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia. celine.valant@monash.edu.ORCID http://orcid.org/0000-0002-2509-7465
David M ThalDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia. david.thal@monash.edu.ORCID http://orcid.org/0000-0002-0325-2524
Australian Research Council · AUStanford University · USMonash University · AUDiscovery Institute · USThe University of Tokyo · JPUniversity of Glasgow · GB

Funding

Discovering the mechanism of GPCR-mediated arrestin stimulation to enable effective drug therapiesR01GM127359 · NIGMS · STANFORD UNIVERSITY · PI DROR, RON · 2018 to 2022
$1.5M
NIGMS NIH HHS R01 GM127359Wellcome Trust 201529
6 · The paper itself

Abstract

The M

Indexed as

Behavior, AddictiveAllosteric SiteBrainCognitionHumansPyridinesThiadiazolesPyridinesThiadiazolesxanomeline

Identifiers

PMID37673901
PMCPMC10482975
OpenAlexW4386481533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.